David Pryor

2.4k total citations
85 papers, 1.4k citations indexed

About

David Pryor is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Surgery. According to data from OpenAlex, David Pryor has authored 85 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 29 papers in Radiation and 27 papers in Surgery. Recurrent topics in David Pryor's work include Advanced Radiotherapy Techniques (29 papers), Prostate Cancer Diagnosis and Treatment (23 papers) and Prostate Cancer Treatment and Research (18 papers). David Pryor is often cited by papers focused on Advanced Radiotherapy Techniques (29 papers), Prostate Cancer Diagnosis and Treatment (23 papers) and Prostate Cancer Treatment and Research (18 papers). David Pryor collaborates with scholars based in Australia, United States and United Kingdom. David Pryor's co-authors include Sandro Porceddu, Bryan Burmeister, Jarad Martin, Michael Poulsen, Shankar Siva, Matthew Foote, Nathan Lawrentschuk, Benedict Panizza, William B. Coman and Elizabeth Burmeister and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and The Journal of Urology.

In The Last Decade

David Pryor

82 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Pryor Australia	20	757	385	382	352	305	85	1.4k
Arya Amini United States	25	1.0k 1.3×	570 1.5×	367 1.0×	694 2.0×	241 0.8×	156	1.9k
Randall Hughes United States	15	889 1.2×	261 0.7×	251 0.7×	631 1.8×	161 0.5×	43	1.4k
Alan Herschtal Australia	25	930 1.2×	317 0.8×	643 1.7×	732 2.1×	133 0.4×	80	2.0k
Gary W. Chmielewski United States	20	1.1k 1.4×	409 1.1×	334 0.9×	253 0.7×	85 0.3×	47	1.4k
Abigail T. Berman United States	28	1.2k 1.6×	230 0.6×	473 1.2×	720 2.0×	91 0.3×	102	1.9k
Daniel Taussky Canada	19	860 1.1×	325 0.8×	214 0.6×	228 0.6×	179 0.6×	133	1.3k
Gabriel Boldt Canada	18	950 1.3×	142 0.4×	388 1.0×	571 1.6×	102 0.3×	89	1.5k
Bryan F. Meyers United States	20	1.9k 2.5×	498 1.3×	491 1.3×	384 1.1×	146 0.5×	45	2.2k
David S. Lamb New Zealand	19	584 0.8×	307 0.8×	213 0.6×	391 1.1×	313 1.0×	30	1.2k
Matthew G. Blum United States	16	1.4k 1.9×	588 1.5×	278 0.7×	442 1.3×	75 0.2×	33	2.0k

Countries citing papers authored by David Pryor

Since Specialization

Citations

This map shows the geographic impact of David Pryor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Pryor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Pryor more than expected).

Fields of papers citing papers by David Pryor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Pryor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Pryor. The network helps show where David Pryor may publish in the future.

Co-authorship network of co-authors of David Pryor

This figure shows the co-authorship network connecting the top 25 collaborators of David Pryor. A scholar is included among the top collaborators of David Pryor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Pryor. David Pryor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Aiqin, Tee Lim, Caroline José, et al.. (2025). LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303). Annals of Oncology. 36. S1628–S1629.

Siva, Shankar, Mathias Bressel, Mark Sidhom, et al.. (2023). TROG 15.03/ANZUP International Multicenter Phase II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II). International Journal of Radiation Oncology*Biology*Physics. 117(2). S3–S3. 6 indexed citations

Liu, Howard, Yoo-Young Lee, Swetha Sridharan, et al.. (2023). Definitive Stereotactic Body Radiation Therapy in Early-Stage Solitary Hepatocellular Carcinoma: An Australian Multi-Institutional Review of Outcomes. Clinical Oncology. 35(12). 787–793. 4 indexed citations

Sidhom, Mark, Paul Keall, Lucy Leigh, et al.. (2023). Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost. International Journal of Radiation Oncology*Biology*Physics. 116(5). 1069–1078. 3 indexed citations

Ali, Muhammad, Simon Wood, David Pryor, et al.. (2023). NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial. Contemporary Clinical Trials Communications. 33. 101145–101145. 4 indexed citations

Lane, Jonathan A., Elizabeth Brown, Sean Bydder, et al.. (2021). Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT. Medical dosimetry. 47(1). 61–69. 2 indexed citations

Nguyen, Doan Trang, T. B. Moodie, Ricky O’Brien, et al.. (2021). Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring. BMC Cancer. 21(1). 494–494. 5 indexed citations

Pryor, David, Mathias Bressel, Nathan Lawrentschuk, et al.. (2021). A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. Contemporary Clinical Trials Communications. 21. 100703–100703. 7 indexed citations

Siva, Shankar, Mathias Bressel, Simon Wood, et al.. (2021). Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. European Urology. 81(4). 364–372. 84 indexed citations

10.

Shanker, Mihir, et al.. (2020). Stereotactic Ablative Radiotherapy For Hepatocellular Carcinoma: A Systematic Review And Meta-Analysis Of Local Control, Survival, And Toxicity Outcomes. International Journal of Radiation Oncology*Biology*Physics. 108(3). e595–e595. 1 indexed citations

11.

Kneebone, Andrew, Amy Hayden, David Christie, et al.. (2019). Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology. 140. 68–75. 24 indexed citations

12.

Pryor, David, et al.. (2019). Efficacy and toxicity of stereotactic radiation therapy in early and advanced stage hepatocellular carcinoma. Journal of Gastroenterology and Hepatology. 34. 34–35. 1 indexed citations

13.

Pryor, David, Mark Sidhom, Sankar Arumugam, et al.. (2019). Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS). Frontiers in Oncology. 9. 217–217. 27 indexed citations

14.

Hayden, Amy, David Christie, Brian J. Davis, et al.. (2018). Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology. 129(2). 377–386. 46 indexed citations

15.

Owen, Rebecca, Catriona Hargrave, David Pryor, et al.. (2017). A Comparison of Non-coplanar Three-dimensional Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, and Volumetric Modulated Radiation Therapy for the Delivery of Stereotactic Ablative Radiation Therapy to Peripheral Lung Cancer. Journal of medical imaging and radiation sciences. 48(4). 360–369. 3 indexed citations

16.

Wu, V., et al.. (2017). Vector-model-supported approach in prostate plan optimization. Medical dosimetry. 42(2). 79–84. 5 indexed citations

17.

Owen, Rebecca, Catriona Hargrave, David Pryor, et al.. (2016). A comparison of three different VMAT techniques for the delivery of lung stereotactic ablative radiation therapy. QUT ePrints (Queensland University of Technology). 1 indexed citations

18.

Antonsson, Annika, Rachel Ε. Neale, Guy Lampe, et al.. (2015). Human papillomavirus status and p16INK4A expression in patients with mucosal squamous cell carcinoma of the head and neck in Queensland, Australia. Cancer Epidemiology. 39(2). 174–181. 41 indexed citations

19.

Pryor, David, Sandro Porceddu, Paul Scuffham, et al.. (2012). Economic analysis of FDG‐PET–guided management of the neck after primary chemoradiotherapy for node‐positive head and neck squamous cell carcinoma. Head & Neck. 35(9). 1287–1294. 31 indexed citations

20.

Porceddu, Sandro, David Pryor, Elizabeth Burmeister, et al.. (2011). Results of a prospective study of positron emission tomography–directed management of residual nodal abnormalities in node‐positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head & Neck. 33(12). 1675–1682. 131 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact